Alogliptin
As of the edition of 20 October 2026, Alogliptin is a small molecule: marketed, first approved in 2010 (JP); acts on DPP4; US protection ends in 2028.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Small molecule
- Brand name
- Oseni
- First approved
- 16 April 2010 (JP)
- Approvals on record
- 26 in 4 regions
- Holder of the most recent approval
- Takeda
- Registered trials
- 52, 3 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive; Cancer; Heart and blood vessels
US protection
US protection ends in 2028.
The last listed US drug-substance patent ends in 2028. The application that gives this date is held by Takeda.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product16 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 16 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DPP4 | Dipeptidyl peptidase 4 | P27487 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 9 | 1 | 1 |
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 23 | 23 | 0 | 0 |
| Phase 4 | 8 | 6 | 0 | 2 |
| All trials | 52 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Takeda | Applicant and Lead sponsor of trials | 2005 to now |